Viatris Publishes Sustainability Report Highlighting 2021 Progress, Achievements and Objectives

PITTSBURGH, Could 16, 2022 /PRNewswire/ — Viatris Inc. (NASDAQ: VTRS), a worldwide pharmaceutical firm, right this moment revealed its 2021 Sustainability Report, outlining the corporate’s 2021 achievements and progress throughout key areas together with Entry and International Well being, Staff, Environmental Stewardship and Group Engagement and together with particulars on Viatris’ continued efforts to assist workers and their households whereas sustaining a secure provide of medicines through the ongoing COVID-19 pandemic.

View PDF

As a part of the report, the corporate dedicated to preliminary company-wide and multi-year targets in three key areas – entry, the setting and variety, fairness and inclusion (DE&I).  These embrace offering antiretroviral (ARV) remedy equal to a complete of 30 million sufferers, together with greater than two million youngsters residing with HIV/ AIDS, between 2022 and the top of 2025; impacting 100 million sufferers through healthcare skilled schooling and outreach concerning prevention, analysis and therapy choices for heart problems, diabetes, most cancers and different essential persistent situations to enhance outcomes by means of the NCD Academy by the top of 2025. Viatris has dedicated to decreasing absolute Scope 1 and a pair of greenhouse fuel (GHG) emissions 42% by 2030 and decreasing Scope 3 GHG emissions overlaying buy items and companies, capital items, gas and vitality associated alternate options and upstream transportation and distribution 25% by 2030. The corporate has additionally set targets to boost DE&I in assist of attracting, growing and retaining numerous expertise and constructing a extra inclusive setting.

“At Viatris, we imagine firms generally is a drive for good. Our colleagues world wide try to make a constructive distinction and through our first full 12 months as Viatris, they really exemplified the facility that lies in collaboration, focus and resilience,” stated Michael Goettler, CEO for Viatris. “We’re happy with the sturdy basis we’ve got constructed, the progress we’ve got made and our dedication to performing responsibly as we assist offering sustainable entry to medication for sufferers world wide, no matter geography or circumstance, whereas constructing a less complicated, stronger and extra centered firm.”

Listed here are a few of Viatris’ key initiatives, progress and accomplishments in 2021, in collaboration with our companions:

• Roughly 40% of adults and greater than 60% of kids being handled for HIV used a Viatris product
• Greater than 80 billion doses of drugs bought throughout greater than 165 international locations and territories, reaching roughly 90% of low- and lower-middle-income international locations with roughly 7.7 billion doses
• Established a proper program for constructing DE&I, starting with understanding the present make-up of our workforce to tell how we are going to embed DE&I all through the group, assist illustration and improve the worker expertise total
• Signed on to the UN International Compact CEO Water Mandate and UN Ladies’s Empowerment Rules
• Roughly 500 million doses of medicines donated throughout a wide range of therapeutic areas by working by means of a trusted community of companions

“At Viatris, our dedication to entry to medication and supporting resilient healthcare methods by advancing sustainable and accountable operations really is a collective mission, realized by means of the dedication of colleagues throughout the group,” stated Lara Ramsburg, Head of Company Affairs of Viatris.

Viatris is devoted to clear annual reporting on environmental, social and governance issues, constantly working to additional improve its disclosures.

To study extra about how the corporate companions with stakeholders all through the globe to deal with a number of the world’s most urgent well being, environmental and social points, click on right here.

About Viatris

Viatris Inc. (NASDAQ: VTRS) is a brand new form of healthcare firm, empowering individuals worldwide to reside more healthy at each stage of life. We offer entry to medicines, advance sustainable operations, develop modern options and leverage our collective experience to attach extra individuals to extra services by means of our one-of-a-kind International Healthcare Gateway®. Shaped in November 2020, Viatris brings collectively scientific, manufacturing and distribution experience with confirmed regulatory, medical, and industrial capabilities to ship high-quality medicines to sufferers in additional than 165 international locations and territories. Viatris’ portfolio includes greater than 1,400 accredited molecules throughout a variety of therapeutic areas, spanning each non-communicable and infectious ailments, together with globally acknowledged manufacturers, complicated generic and branded medicines, a portfolio of biosimilars and a wide range of over-the-counter shopper merchandise. With roughly 37,000 colleagues globally, Viatris is headquartered within the U.S., with international facilities in Pittsburgh, Shanghai and Hyderabad, India. Study extra at viatris.com and investor.viatris.com, and join with us on Twitter at @ViatrisInc, LinkedIn and YouTube. 

Ahead-Trying Statements

This press launch consists of statements that represent “forward-looking statements.” These statements are made pursuant to the protected harbor provisions of the Non-public Securities Litigation Reform Act of 1995. Such ahead wanting statements might embrace statements concerning the firm committing to preliminary company-wide and multi-year targets in three key areas – entry, the setting and DE&I; that these embrace offering antiretroviral (ARV) remedy equal to a complete of 30 million sufferers, together with greater than two million youngsters residing with HIV/ AIDS, between 2022 and the top of 2025; affect 100 million sufferers through healthcare skilled schooling and outreach concerning prevention, analysis and therapy choices for heart problems, diabetes, most cancers and different essential persistent situations to enhance outcomes by means of the NCD Academy by the top of 2025; that Viatris has dedicated to decreasing absolute Scope 1 and a pair of greenhouse fuel (GHG) emissions 42% by 2030 and decreasing Scope 3 GHG emissions overlaying buy items and companies, capital items, gas and vitality associated alternate options and upstream transportation and distribution 25% by 2031; and that the corporate has additionally set targets to boost DE&I in assist of attracting, growing and retaining numerous expertise and constructing a extra inclusive setting. As a result of forward-looking statements inherently contain dangers and uncertainties, precise future outcomes might differ materially from these expressed or implied by such statements. Components that might trigger or contribute to such variations embrace, however should not restricted to: the potential affect of public well being outbreaks, epidemics and pandemics, together with the continued challenges and uncertainties posed by the COVID-19 pandemic; the pending transaction between Viatris and Biocon Biologics Restricted, pursuant to which Viatris will contribute its biosimilar merchandise and packages to Biocon Biologics in alternate for money consideration and a convertible most well-liked fairness curiosity in Biocon Biologics, might not obtain its meant advantages; the mixing of Mylan N.V. and Pfizer Inc.’s Upjohn enterprise (the “Upjohn Enterprise”), which mixed to kind Viatris (the “Mixture”) and the implementation of our international restructuring initiatives being harder, time consuming or pricey than anticipated, or being unsuccessful; the power to realize anticipated advantages, synergies, and working efficiencies in reference to the Mixture or its restructuring initiatives throughout the anticipated timeframe or in any respect; actions and selections of healthcare and pharmaceutical regulators; modifications in healthcare and pharmaceutical legal guidelines and rules within the U.S. and overseas; any regulatory, authorized or different impediments to Viatris’ capacity to carry new merchandise to market, together with however not restricted to “at-risk” launches; Viatris’ or its companions’ capacity to develop, manufacture, and commercialize merchandise; the scope, timing and consequence of any ongoing authorized proceedings, and the affect of any such proceedings; any important breach of information safety or information privateness or disruptions to our info know-how methods; dangers related to worldwide operations; the power to guard mental property and protect mental property rights; modifications in third-party relationships; the impact of any modifications in Viatris’ or its companions’ buyer and provider relationships and buyer buying patterns; the impacts of competitors; modifications within the financial and monetary situations of Viatris or its companions; uncertainties and issues past the management of administration; and the opposite dangers described in Viatris’ filings with the Securities and Change Fee (SEC). Viatris routinely makes use of its web site as a method of revealing materials info to the general public in a broad, non-exclusionary method for functions of the SEC’s Regulation Truthful Disclosure (Reg FD). Viatris undertakes no obligation to replace these statements for revisions or modifications after the date of this launch apart from as required by legislation.

SOURCE Viatris Inc.